Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Aft Pharmaceuticals Ltd

Healthcare AU AFP

3.0AUD
-(-%)

Last update at 2026-03-10T02:33:00Z

Day Range

3.003.00
LowHigh

52 Week Range

2.203.37
LowHigh

Fundamentals

  • Previous Close 3.00
  • Market Cap329.67M
  • Volume1000
  • P/E Ratio23.85
  • Dividend Yield0.58%
  • EBITDA25.23M
  • Revenue TTM236.25M
  • Revenue Per Share TTM2.25
  • Gross Profit TTM 105.20M
  • Diluted EPS TTM0.13

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax 16.03M 22.02M 15.80M 18.68M 7.89M
Minority interest 0.56M - - - -
Net income 11.96M 15.61M 10.65M 19.85M 7.78M
Selling general administrative 12.23M 11.21M 11.12M 7.77M 7.78M
Selling and marketing expenses 51.09M 45.26M 38.28M 30.22M 28.90M
Gross profit 89.19M 86.89M 72.98M 61.77M 48.74M
Reconciled depreciation 2.67M 2.01M 1.72M 1.04M 1.10M
Ebit 18.86M 25.70M 19.67M 20.39M 10.71M
Ebitda 21.52M 27.72M 19.88M 20.67M 10.97M
Depreciation and amortization 2.67M 2.01M 0.21M 0.28M 0.26M
Non operating income net other - - - - -
Operating income 11.70M 20.32M 19.67M 20.39M 10.71M
Other operating expenses 193.79M 173.72M 137.98M 109.20M 101.78M
Interest expense 2.82M 3.69M 2.87M 2.44M 3.44M
Tax provision 4.63M 6.41M 5.14M -1.16300M 0.10M
Interest income 0.03M 0.07M 0.01M 0.00400M 0.00400M
Net interest income -2.79600M -3.62000M -2.86000M -2.43100M -3.43700M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 4.63M 6.41M 5.14M 1.16M 0.10M
Total revenue 205.49M 194.03M 156.64M 130.31M 113.11M
Total operating expenses 77.49M 66.58M 54.32M 40.66M 37.42M
Cost of revenue 116.31M 107.14M 83.66M 68.54M 64.36M
Total other income expense net 4.33M 1.70M -3.87000M -1.70400M -2.82100M
Discontinued operations - - - - -
Net income from continuing ops 11.40M 15.61M 10.65M 19.85M 7.78M
Net income applicable to common shares - - 10.65M 19.85M 7.59M
Preferred stock and other adjustments - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets - 165.26M 148.06M 121.76M 105.13M
Intangible assets - 53.46M 45.63M 38.09M 32.72M
Earning assets - - - - -
Other current assets - 0.41M 7.84M 6.24M 1.81M
Total liab - 77.46M 74.80M 65.02M 68.54M
Total stockholder equity - 87.80M 73.27M 56.74M 36.59M
Deferred long term liab - - 29.46M 22.11M 17.13M
Other current liab - 11.93M 17.59M 16.98M 17.40M
Common stock - 78.24M 78.24M 77.61M 77.20M
Capital stock - - 78.24M 77.61M 77.20M
Retained earnings - 9.26M -5.19800M -21.41600M -41.26400M
Other liab - - - - 3.24M
Good will - - - - -
Other assets - - 33.93M 24.87M 17.86M
Cash - 12.04M 4.75M 7.94M 3.21M
Cash and equivalents - - - - -
Total current liabilities - 46.07M 39.77M 29.05M 32.10M
Current deferred revenue - - -3.02900M -4.54200M -5.77500M
Net debt - 19.35M 33.30M 32.57M 39.01M
Short term debt - - 3.03M 4.54M 5.78M
Short long term debt - - 2.46M 4.00M 5.16M
Short long term debt total - 31.39M 38.05M 40.51M 42.22M
Other stockholder equity - - -2.94000M -2.61000M -2.50700M
Property plant equipment - - 3.37M 3.36M 3.79M
Total current assets - 105.73M 94.60M 77.54M 67.90M
Long term investments - - - - -
Net tangible assets - - 57.10M 40.76M 21.00M
Short term investments - - - - -
Net receivables - 44.22M 39.62M 29.87M 29.23M
Long term debt - - 32.20M 33.20M 33.20M
Inventory - 49.06M 42.40M 33.50M 33.65M
Accounts payable - 34.14M 22.18M 12.07M 14.70M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.30M 0.23M 0.55M 0.66M
Additional paid in capital - - - - -
Common stock total equity - - - - 77.20M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 2.25M -19.53300M -19.34800M -19.37400M
Deferred long term asset charges - - - - -
Non current assets total - 59.53M 53.46M 44.22M 37.23M
Capital lease obligations - - 3.39M 3.31M 3.86M
Long term debt total - - - - 36.44M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -6.95100M -9.52700M -9.17700M -5.58500M -6.23100M
Change to liabilities - - 12.67M -2.66300M 3.84M
Total cashflows from investing activities -6.95100M -9.52700M -9.17700M -5.58500M -6.23100M
Net borrowings -1.51700M -5.00000M -4.59300M -2.01700M -5.49200M
Total cash from financing activities -6.81100M -10.63300M -6.97800M -2.27600M 2.52M
Change to operating activities - - - - -
Net income 11.96M 15.61M 10.65M 19.85M 7.78M
Change in cash -0.93000M 8.75M -4.64900M 4.73M -2.91000M
Begin period cash flow 12.04M 3.29M 7.94M 3.21M 6.12M
End period cash flow 11.11M 12.04M 3.29M 7.94M 3.21M
Total cash from operating activities 13.18M 28.86M 11.63M 14.15M 0.75M
Issuance of capital stock - - 0.47M 0.29M 12.40M
Depreciation - 2.01M 0.85M 0.91M 0.97M
Other cashflows from investing activities -6.67000M -9.41100M - - -6.23100M
Dividends paid -1.67800M -1.15400M - - 0.19M
Change to inventory 0.58M -6.66000M -8.89700M 0.15M -10.92000M
Change to account receivables -4.34200M 2.50M -10.71600M -4.96300M -4.55600M
Sale purchase of stock - - - - -0.72300M
Other cashflows from financing activities -3.61600M -4.47900M -2.86000M 2.81M -2.46300M
Change to netincome - - 6.20M 0.73M 3.50M
Capital expenditures 6.95M 9.53M 0.20M 0.33M 6.23M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -3.76100M -4.16400M -19.61300M -4.80900M -15.47600M
Stock based compensation - 0.14M - 0.01M 0.04M
Other non cash items 16.94M 15.26M 19.74M -6.60900M -8.00700M
Free cash flow 6.22M 19.33M 11.43M 13.82M -5.48100M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AFP
Aft Pharmaceuticals Ltd		 - -% 3.00 23.85 19.88 1.40 3.89 1.68 13.38
VLS
Vita Life Sciences Ltd		 -0.04 1.57% 2.51 14.06 42.73 1.51 2.56 1.19 7.04
SNT
Syntara Ltd		 0.001 3.33% 0.03 - 22.83 6.97 4.78 6.13 -2.1607
MVP
Medical Developments International Ltd		 0.005 1.25% 0.41 - 166.67 1.19 0.88 0.82 12.54
LGP
Little Green Pharma Ltd		 0.01 15.00% 0.12 5.50 43.29 0.87 0.39 0.94 18.70

Reports Covered

Stock Research & News

View All

Profile

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, dermatology, and hospital. It has a research and development collaboration with Belgium's Hyloris Pharmaceuticals to develop a novel innovative injectable iron deficiency therapy. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.

Aft Pharmaceuticals Ltd

129 Hurstmere Road, Auckland, New Zealand, 0622

Key Executives

Name Title Year Born
Dr. Hartley Atkinson Ph.D. Co-Founder, CEO, MD & Exec. Director NA
Ms. Marree Atkinson Co-Founder, Chief of Staff & Exec. Director NA
Mr. Malcolm Tubby B.A., BA(Hon's), ICAEW, ICANZ CFO & Company Sec. NA
Mr. Murray Keith Group Marketing Mang. NA
Ms. Ioana Stanescu Head of Drug Devel. NA
Mr. Calvin Mackenzie Gen. Mang. of AFT Australia NA
Mr. Scott Crawford Gen. Mang. of Promoted Products Australasia & South East Asia NA
Ms. Louise Clayton Director of International Bus. NA
Dr. Hartley Atkinson Ph.D. Co-Founder, CEO, MD & Executive Director NA
Ms. Marree Atkinson Co-Founder, Chief of Staff & Executive Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.